CEBINA and Danube BioVentures announce the launch of TAG Therapeutics

Danube Labs, a life science acceleration partnership formed by CEBINA GmbH (Central European Biotech Incubator and Accelerator), Evotec SE and the biotech fund Danube BioVentures, announces the launch of TAG Therapeutics, a biotech start-up developing Teloblock, an antisense oligonucleotide (ASO)-based precision medicine approach to tackle telomere pathologies and age-related diseases.